Shire News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

25.04.17	Shire to Participate at the Deutsche Bank 42nd Annual Health Care Conference (PR Newswire)
25.04.17	Shire to Participate at the Deutsche Bank 42nd Annual Health Care Conference (PR Newswire)
24.04.17	Shire Launches #PIPostsThanks Social Campaign to Raise Awareness of Primary Immunodeficiency (PI) (PR Newswire)
24.04.17	Shire Launches #PIPostsThanks Social Campaign to Raise Awareness of Primary Immunodeficiency (PI) (PR Newswire)
17.04.17	Shire Data Show Bleeding Episode Occurs More Than 3 Times Current Global View (RTTNews)
17.04.17	Shire plc: Data Show A Bleeding Episode Occurs Every Three to 15 Seconds in People Living With Hemophilia Worldwide (PR Newswire)
17.04.17	Shire plc: Data Show A Bleeding Episode Occurs Every Three to 15 Seconds in People Living With Hemophilia Worldwide (PR Newswire)
31.03.17	How These Healthcare Stocks are Faring? -- GlaxoSmithKline, Universal Health Services, Shire, and LifePoint Health (PR Newswire)
30.03.17	Shire Partner Receives Approval For INTUNIV In Japan To Treat ADHD In Children (RTTNews)
30.03.17	INTUNIV® (Guanfacine Hydrochloride Prolonged Release), a Non-stimulant for the Treatment of ADHD, Receives Approval in Japan (PR Newswire)
30.03.17	INTUNIV® (Guanfacine Hydrochloride Prolonged Release), a Non-stimulant for the Treatment of ADHD, Receives Approval in Japan (PR Newswire)
22.03.17	Shire Receives FDA Fast Track Designation for Recombinant ADAMTS13 (SHP655) for Treatment of Hereditary Thrombotic Thrombocytopenic Purpura (PR Newswire)
16.03.17	Shire Receives European Approval for Label Extension of CINRYZE®▼(C1 inhibitor [human]) to Prevent and Treat Hereditary Angioedema (HAE) Attacks in Paediatric Patients with HAE (PR Newswire)
16.03.17	Shire Receives European Approval for Label Extension of CINRYZE®▼(C1 inhibitor [human]) to Prevent and Treat Hereditary Angioedema (HAE) Attacks in Paediatric Patients with HAE (PR Newswire)
06.03.17	CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] Data Demonstrate Improved Treatment Satisfaction Relative to Patients' Previous Immunoglobulin Therapy (PR Newswire)
01.03.17	Shire to Participate at the Cowen 37th Annual Healthcare Conference (PR Newswire)
01.03.17	Shire to Participate at the Cowen 37th Annual Healthcare Conference (PR Newswire)
24.02.17	Shire: CHMP Recommends EU Conditional Marketing Authorisation For Natpar (RTTNews)
24.02.17	CHMP Recommends EU Conditional Marketing Authorisation for Natpar® (Parathyroid Hormone) for Patients with Chronic Hypoparathyroidism (PR Newswire)
24.02.17	CHMP Recommends EU Conditional Marketing Authorisation for Natpar® (Parathyroid Hormone) for Patients with Chronic Hypoparathyroidism (PR Newswire)
23.02.17	New England Journal of Medicine Publishes Phase 1b Results for Shire's Investigational Treatment for Hereditary Angioedema, a Rare Genetic Disease (PR Newswire)
23.02.17	New England Journal of Medicine Publishes Phase 1b Results for Shire's Investigational Treatment for Hereditary Angioedema, a Rare Genetic Disease (PR Newswire)
23.02.17	Shire Launches 'Rare Count' Campaign to Personalize the Global Impact of Rare Diseases (PR Newswire)
23.02.17	Shire Launches 'Rare Count' Campaign to Personalize the Global Impact of Rare Diseases (PR Newswire)
16.02.17	How These Healthcare Stocks are Faring? -- GlaxoSmithKline, Shire, Pacira Pharma, and Supernus Pharma (PR Newswire)
16.02.17	Shire Reports Full Year 2016 Results With Record Revenue; Positioned for Continued Strong Growth Driven by Best-in-class Rare Disease Pipeline (PR Newswire)
16.02.17	Shire Reports Full Year 2016 Results With Record Revenue; Positioned for Continued Strong Growth Driven by Best-in-class Rare Disease Pipeline (PR Newswire)
16.02.17	Shire Q4 Results Top Estimates; Expects 2017 To Be Another Strong Year (RTTNews)
14.02.17	Shire to Highlight Advancements in Rare Genetic Diseases (PR Newswire)
07.02.17	Shire Responds to U.S. Federal Trade Commission Civil Action (PR Newswire)
07.02.17	Shire Responds to U.S. Federal Trade Commission Civil Action (PR Newswire)
01.02.17	New Data From Shire Aim to Help Close the Diagnosis and Treatment Gap for People With Hemophilia (PR Newswire)
01.02.17	New Data From Shire Aim To Help Close the Diagnosis and Treatment Gap for People With Hemophilia (PR Newswire)
20.01.17	ADMP Waiting To See If 3rd Time Is Charm, FDA Nod For SGYP, Be All Ears For OTIC (RTTNews)
19.01.17	FDA Acknowledges Receipt Of Shire' NDA For SHP465 For ADHD (RTTNews)
19.01.17	U.S. FDA Acknowledges Receipt of Shire's New Drug Application for SHP465 for ADHD (PR Newswire)
19.01.17	U.S. FDA Acknowledges Receipt of Shire's New Drug Application for SHP465 for ADHD (PR Newswire)
09.01.17	Technical Reports on Healthcare Stocks -- CVS Health, UnitedHealth, Express Scripts, and Shire (PR Newswire)
06.01.17	Xenetic Gets $3 Mln Milestone Payment From Shire PSA-Recombinant SHP656 (RTTNews)
28.12.16	ANTH Plunges On Failed SOLUTION, All Eyes On CEMP, FDA Says No To AMPH Again (RTTNews)
27.12.16	Shire Plc Announces New FDA-approved Indications For ADYNOVATE - Quick Facts (RTTNews)
27.12.16	Shire Announces FDA Approval of Adynovate® [Antihemophilic Factor (Recombinant), Pegylated] for use in Children and Surgical Settings (PR Newswire)
27.12.16	Shire Announces FDA Approval of Adynovate® [Antihemophilic Factor (Recombinant), Pegylated] for use in Children and Surgical Settings (PR Newswire)
05.12.16	ALNY In Motion, Shire Finds New Use For Old Drug, TFX Snaps Up VASC (RTTNews)
05.12.16	ALNY In Motion, Shire Finds New Use For Old Drug, TFX Snaps Up VASC (RTTNews)
02.12.16	Shire Reports on Four Decades of Real-World Safety Experience With FEIBA® [Anti-Inhibitor Coagulant Complex] (PR Newswire)
02.12.16	Shire Reports on Four Decades of Real-World Safety Experience With FEIBA® [Anti-Inhibitor Coagulant Complex] (PR Newswire)
02.12.16	BetterInvesting Magazine Releases February Stock To Study And Undervalued Stock Choices For Investors' Informational And Educational Use (PR Newswire)
02.12.16	Topline Results of Phase 3 Investigational Study of VONVENDI™ [von Willebrand factor (recombinant)] Meets Primary Endpoint Effectively Controlling Bleeding and Blood Loss During Surgical Procedures (PR Newswire)
02.12.16	Topline Results of Phase 3 Investigational Study of VONVENDI™ [von Willebrand factor (recombinant)] Meets Primary Endpoint Effectively Controlling Bleeding and Blood Loss During Surgical Procedures (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Shire plc (Spons. ADRs)

Aktien Top/Flop

Meistgelesene Nachrichten